Fulcrum Therapeutics (FULC)


Market Price (11/18/2026): $3.75 | Market Cap: $286.4 MilSector: Health Care | Industry: Biotechnology

Fulcrum Therapeutics (FULC)


Market Price (11/18/2026): $3.75
Market Cap: $286.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -105%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.

Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -61%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -76 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32%

Key risks
FULC key risks include [1] heightened development uncertainty for its lead candidate, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -105%
1 Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.
2 Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -61%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -76 Mil
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32%
6 Key risks
FULC key risks include [1] heightened development uncertainty for its lead candidate, Show more.

FULC in ETFs

Weight = FULC's share of each fund

VTI0.00%
ITOT0.00%
IWM0.01%
IBB0.02%
IWN0.02%
VTWO0.01%
SCHA0.01%
VHT0.00%
+4 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Down 62.1% from its Apr 17 high to Jun 2, up 19.4% since (S&P 500 up 7.0%)
The stock declined sharply as the company discontinued its Pociredir program due to FDA feedback regarding cancer-risk concerns. This was announced on June 1 and drove further steep declines on June 2 following reports on the cancer-risk concerns.

Show more
Prices as of 11/17/2026

Down 62.1% from its Apr 17 high to Jun 2, up 19.4% since (S&P 500 up 7.0%)
The stock declined sharply as the company discontinued its Pociredir program due to FDA feedback regarding cancer-risk concerns. This was announced on June 1 and drove further steep declines on June 2 following reports on the cancer-risk concerns.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 4.7% change in FULC stock from 7/31/2026 to 11/17/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611172026Change
Stock Price ($)3.583.754.7%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)7676-0.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
FULC4.7% 
Market (SPY)-1.7%41.1%
Sector (XLV)14.4%14.5%

Fundamental Drivers

The -47.4% change in FULC stock from 4/30/2026 to 11/17/2026 was primarily driven by a -0.1% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611172026Change
Stock Price ($)7.133.75-47.4%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)7676-0.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
FULC-47.4% 
Market (SPY)2.4%3.1%
Sector (XLV)27.9%16.8%

Fundamental Drivers

The -57.1% change in FULC stock from 10/31/2025 to 11/17/2026 was primarily driven by a -18.0% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)8.753.75-57.1%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)6376-18.0%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
FULC-57.1% 
Market (SPY)8.5%7.3%
Sector (XLV)30.6%10.5%

Fundamental Drivers

The 3.0% change in FULC stock from 10/31/2023 to 11/17/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.
(LTM values as of)1031202311172026Change
Stock Price ($)3.643.753.0%
Change Contribution By: 
Total Revenues ($ Mil)30 
P/S Multiple73.9∞9.2233720368547763E17%
Shares Outstanding (Mil)6276-19.0%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
FULC3.0% 
Market (SPY)81.6%21.5%
Sector (XLV)56.4%17.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
FULC Return51%-59%-7%-30%141%-67%-68%
Peers Return43%-20%3%78%-33%-20%13%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
FULC Win Rate33%50%58%50%50%27% 
Peers Win Rate46%50%46%58%75%32% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
FULC Max Drawdown-55%-82%-84%-75%-51%-73% 
Peers Max Drawdown-41%-46%-34%-26%-59%-52% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ASPE, ATYR, BBTX, CTY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventFULCS&P 500
2025 US Tariff Shock
  % Loss-34.6%-18.8%
  % Gain to Breakeven53.0%23.1%
  Time to Breakeven26 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-13.4%-9.5%
  % Gain to Breakeven15.4%10.5%
  Time to Breakeven5 days24 days
2023 SVB Regional Banking Crisis
  % Loss-82.0%-6.7%
  % Gain to Breakeven456.2%7.1%
  Time to Breakeven971 days31 days
2020 COVID-19 Crash
  % Loss-47.0%-33.7%
  % Gain to Breakeven88.7%50.9%
  Time to Breakeven38 days140 days

Compare to VRTX, ASPE, ATYR, BBTX, CTY

In The Past

Fulcrum Therapeutics's stock fell -34.6% during the 2025 US Tariff Shock. Such a loss loss requires a 53.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventFULCS&P 500
2025 US Tariff Shock
  % Loss-34.6%-18.8%
  % Gain to Breakeven53.0%23.1%
  Time to Breakeven26 days79 days
2023 SVB Regional Banking Crisis
  % Loss-82.0%-6.7%
  % Gain to Breakeven456.2%7.1%
  Time to Breakeven971 days31 days
2020 COVID-19 Crash
  % Loss-47.0%-33.7%
  % Gain to Breakeven88.7%50.9%
  Time to Breakeven38 days140 days

Compare to VRTX, ASPE, ATYR, BBTX, CTY

In The Past

Fulcrum Therapeutics's stock fell -34.6% during the 2025 US Tariff Shock. Such a loss loss requires a 53.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing new treatments for genetically defined diseases that currently have high unmet medical needs. The company's mission is to discover and advance therapies that can significantly improve the lives of patients by addressing the root causes of their conditions.

The company's lead product candidates target specific severe genetic disorders. Losmapimod is a small molecule therapy under development for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive muscle weakening disease. Another key candidate, FTX-6058, is an investigational oral fetal hemoglobin inducer designed to treat sickle cell disease and other related hemoglobinopathies, including beta-thalassemia.

Fulcrum also maintains active research and discovery programs aimed at identifying novel drug targets for a broader spectrum of rare diseases, encompassing neuromuscular, muscular, central nervous system, hematologic disorders, cardiomyopathies, and pulmonary diseases. Its primary customer base consists of patients in the United States affected by these debilitating genetic conditions, underscoring its commitment to specialized medicine.

AI Analysis | Feedback

Here are a few brief analogies for Fulcrum Therapeutics (FULC):

  • An emerging Vertex Pharmaceuticals for other rare genetic diseases.

  • A specialized biotech developing treatments for genetic disorders, similar to a focused, early-stage Biogen.

AI Analysis | Feedback

  • losmapimod: A small molecule in development for the treatment of facioscapulohumeral muscular dystrophy.
  • FTX-6058: An investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies.

AI Analysis | Feedback

Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company focused on the research and development of drug candidates. As such, it does not currently have approved products for commercial sale directly to individual patients or to healthcare providers like hospitals and pharmacies.

Instead, the company's revenue generation at this stage primarily comes from collaboration and licensing agreements with other pharmaceutical companies. Based on the provided background information, its major collaboration partners, which can be considered its primary "customers" or sources of revenue through partnership, are:

  • Acceleron Pharma Inc. (This company was acquired by Merck & Co., Inc. (NYSE: MRK). The collaboration agreement would now be associated with Merck.)
  • MyoKardia, Inc. (This company was acquired by Bristol Myers Squibb Company (NYSE: BMY). The collaboration agreement would now be associated with Bristol Myers Squibb.)

These companies entered into research, discovery, and strategic collaboration agreements with Fulcrum Therapeutics to develop and potentially commercialize novel therapies.

AI Analysis | Feedback

null

AI Analysis | Feedback

Alex C. Sapir
Chief Executive Officer and President

Mr. Sapir is an industry veteran with over two decades of experience in the biopharmaceutical industry. He most recently served as CEO of ReViral Ltd, which was acquired by Pfizer in 2022. Prior to ReViral, he was President and CEO at Dova Pharmaceuticals, where he led its transformation from a private, pre-commercial company to a publicly traded biotech company that was later acquired by Sobi, Inc. Earlier in his career, Mr. Sapir was the Executive Vice President for Marketing and Sales at United Therapeutics and held commercial positions of increasing responsibility at GSK.

Alan A. Musso
Chief Financial Officer

Mr. Musso joined Fulcrum in August 2023 as Chief Financial Officer. Prior to Fulcrum, he served as CFO of ReViral, which was acquired by Pfizer in 2022. Previously, he was the Chief Financial Officer and Treasurer at Peloton Therapeutics Inc., where he secured a $150 million mezzanine financing and prepared the company for a NASDAQ IPO until it was acquired by Merck & Co. Mr. Musso also served as CFO and Treasurer of other biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals.

Curtis Oltmans, JD
General Counsel

Mr. Oltmans joined Fulcrum as General Counsel in November 2020 and brings over 25 years of experience in corporate law. He previously served as Executive Vice President, General Counsel, and Corporate Secretary at Array BioPharma Inc., overseeing all legal, corporate governance, patent, and compliance matters, prior to its acquisition by Pfizer. Mr. Oltmans also served as Corporate Vice President and General Counsel for Novo Nordisk, Inc., North America, and Assistant General Counsel for Eli Lilly and Company.

Lisa Percival
Chief Regulatory & Quality Assurance Officer

Ms. Percival joined Fulcrum in October 2025 as Chief Regulatory & Quality Assurance Officer. Prior to Fulcrum, she served as Senior Vice President, Head of Regulatory at Belenos Bio and Vividion Therapeutics. She also held roles as an entrepreneur in residence, regulatory strategy for Atlas Venture stealth companies, and as Senior Vice President, Regulatory Affairs for Third Harmonic Bio.

Iain Fraser, MBChB, D. Phil.
Senior Vice President, Early Development

Dr. Fraser was named Senior Vice President, Early Development in March 2024, having previously served as Interim Chief Medical Officer from March 2023 to March 2024. He brings over two decades of experience advancing therapies through early- and late-stage development with expertise in clinical development and regulatory affairs. He most recently served as Vice President and Clinical Fellow at AlloVir, an Elevate Bio Company.

AI Analysis | Feedback

The key risks for Fulcrum Therapeutics (FULC) primarily revolve around the inherent challenges of drug development and commercialization in the biopharmaceutical industry.

  1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Fulcrum Therapeutics' success is heavily dependent on its ability to successfully develop and obtain regulatory approval for its product candidates. The discontinuation of their losmapimod program for facioscapulohumeral muscular dystrophy (FSHD) in September 2024, following its failure to meet the primary endpoint in a Phase 3 trial, highlights this significant risk. Their lead remaining candidate, pociredir (formerly FTX-6058) for sickle cell disease, previously faced a full clinical hold by the U.S. Food and Drug Administration (FDA) in February 2023 due to concerns about potential hematological malignancies observed with other polycomb repressive complex 2 (PRC2) inhibitors. Although the clinical hold was lifted in August 2023, the company was requested to further define the patient population where the benefits of pociredir outweigh potential risks, indicating ongoing regulatory scrutiny and the potential for future challenges in demonstrating a favorable benefit-risk profile and securing approval.

  2. Intellectual Property Protection: The ability to obtain, maintain, and protect intellectual property rights, particularly patents, for its drug candidates is crucial for Fulcrum Therapeutics. Without robust intellectual property protection, the company's significant investment in research and development could be undermined by competitors.

  3. Need for Additional Capital: Developing drugs through clinical trials is a capital-intensive process. As a clinical-stage company with no commercialized products generating revenue, Fulcrum Therapeutics is reliant on its existing cash reserves and its ability to raise substantial additional capital to fund its ongoing and future research and development activities, including clinical trials. While the company has indicated a cash runway into 2029, the high costs associated with drug development, coupled with potential setbacks, could necessitate further financing, which may not always be available on favorable terms.

AI Analysis | Feedback

The rapid advancement and growing pipeline of gene therapy and gene-editing technologies for genetically defined diseases pose a significant emerging threat to Fulcrum Therapeutics.

For conditions like sickle cell disease and beta-thalassemia, where Fulcrum's FTX-6058 is an investigational oral fetal hemoglobin inducer, several gene-editing therapies (e.g., Beam Therapeutics' BEAM-101 and Editas Medicine's EDIT-301) are actively progressing through clinical trials. These emerging therapies aim to offer potentially curative, one-time treatments by directly correcting underlying genetic defects, representing a paradigm shift from chronic small molecule management.

This transformative potential of gene therapy and gene editing, which seeks to provide definitive therapeutic options, could fundamentally diminish the long-term market opportunity and clinical relevance for Fulcrum's small molecule product candidates targeting these diseases.

Similarly, for facioscapulohumeral muscular dystrophy (FSHD), where Fulcrum's losmapimod is in development, gene therapies (e.g., Atamyo Therapeutics' ATA-100) and RNA therapeutics (e.g., Avidity Biosciences' AOC 1027) are also progressing through clinical development. While currently in earlier stages, these modalities represent an emerging future for FSHD treatment that could offer more profound and lasting effects compared to small molecule approaches, potentially rendering such approaches less competitive over time.

AI Analysis | Feedback

Fulcrum Therapeutics (symbol: FULC) operates in the addressable markets for Facioscapulohumeral Muscular Dystrophy (FSHD), Sickle Cell Disease, and Beta-thalassemia.

Losmapimod (Facioscapulohumeral Muscular Dystrophy - FSHD)

  • The global Facioscapulohumeral Muscular Dystrophy (FSHD) market was valued at approximately USD 210 million in 2024 and is projected to reach USD 482 million by 2034, at a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period (2025-2034).
  • In the seven major markets (7MM), which include the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, the FSHD market reached a value of USD 32.2 million in 2024. This market is expected to reach USD 61.4 million by 2035, exhibiting a CAGR of 6.12% during 2025-2035.
  • The United States accounts for the largest market share (around 80%) of the FSHD market within the 7MM.

FTX-6058 (Sickle Cell Disease and Beta-thalassemia)

Sickle Cell Disease

  • The global sickle cell disease treatment market size was estimated at USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030, growing at a CAGR of 15.7% from 2024 to 2030.
  • Another estimate places the global sickle cell disease treatment market size at USD 3.94 billion in 2025, projected to reach USD 20.47 billion by 2034, exhibiting a CAGR of 20.10% from 2026 to 2034.
  • In the U.S., the sickle cell disease treatment market generated a revenue of USD 951.7 million in 2023 and is expected to reach USD 2,401.9 million by 2030.
  • The U.S. sickle cell disease treatment market size was valued at USD 1.44 billion in 2022 and is projected to grow at a CAGR of 17.3% during the forecast period.

Beta-thalassemia

  • The beta thalassemia market in the United States was valued at approximately USD 358 million in 2023 and is projected to expand significantly by 2034.
  • The U.S. Beta Thalassemia Market is estimated at USD 0.67 billion in 2024 and is projected to reach approximately USD 1.02 billion by 2030, with a CAGR of 7.4%.
  • Across the top 7 markets (US, EU4, UK, and Japan), the beta thalassemia market reached a value of USD 368.7 million in 2024 and is expected to reach USD 901.7 million by 2035, exhibiting a CAGR of 8.48% during 2025-2035.

AI Analysis | Feedback

Fulcrum Therapeutics (FULC) is expected to drive future revenue growth over the next two to three years primarily through the advancement and potential commercialization of its lead product candidates and strategic collaborations:

  1. Commercialization of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) in the U.S. Fulcrum Therapeutics retains full U.S. commercialization rights for losmapimod, its investigational oral small molecule for the treatment of FSHD. The company anticipates reporting topline data from the global Phase 3 REACH clinical trial in the fourth quarter of 2024. Following positive Phase 3 data, Fulcrum and its partner Sanofi plan to submit marketing applications in the U.S., Europe, Japan, and other geographies, positioning losmapimod for potential market entry and revenue generation in the U.S. within the next 2-3 years.
  2. Milestone Payments and Royalties from Sanofi Collaboration for Losmapimod (ex-U.S.). In May 2024, Fulcrum entered a collaboration and license agreement with Sanofi, granting Sanofi exclusive commercialization rights for losmapimod outside the U.S. Under this agreement, Fulcrum received an upfront payment of $80 million and is eligible to receive up to an additional $975 million in specified regulatory and sales-based milestones, along with tiered escalating royalties on annual net sales of losmapimod outside the U.S. These milestone payments and future royalties are expected to contribute significantly to Fulcrum's revenue as losmapimod progresses through regulatory approvals and commercialization in international markets.
  3. Advancement and Potential Commercialization of Pociredir (FTX-6058) for Sickle Cell Disease. Fulcrum's investigational oral fetal hemoglobin inducer, pociredir (FTX-6058), is being developed for the treatment of sickle cell disease (SCD). The company has reported promising 12-week outcomes from its Phase 1b PIONEER trial, demonstrating significant increases in fetal hemoglobin levels. Analysts project substantial revenue growth for Fulcrum, estimating $560 million by 2028, primarily driven by the anticipated market opportunities in SCD due to a lack of existing treatment options. Fulcrum is progressing towards a Phase 3 trial for pociredir in the second half of 2026, which, if successful, could lead to its eventual commercialization and significant revenue streams.

AI Analysis | Feedback

Share Issuance

  • In December 2025, Fulcrum Therapeutics completed a public offering of common stock and pre-funded warrants, generating net proceeds of $164.2 million.
  • The company's common stock issuance totaled $186.53 million in 2021, $84.32 million in 2022, and $118.12 million in 2023.
  • Shares outstanding increased to 67 million in Q4 2025, marking a 23.0% increase from the prior quarter.

Inbound Investments

  • Fulcrum Therapeutics received net proceeds of $164.2 million from a public offering of its common stock and pre-funded warrants in December 2025.
  • As of December 31, 2025, the company's cash, cash equivalents, and marketable securities stood at $352.3 million, extending its cash runway into 2029.

Capital Expenditures

  • Capital expenditures were $0.159 million in Q4 2025.
  • Annual capital expenditures were approximately $1.71 million in 2021, $1.96 million in 2022, $0.51 million in 2023, $0.28 million in 2024, and $0.39 million in 2025.
  • These expenditures are primarily focused on funding long-term assets and infrastructure.

Peer Outperformance in Biotechnology

FULC has outperformed 55% of its 369 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that FULC has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
30%
of 453 industry peers · -61.1% return
3Y
59%
of 399 industry peers · -9.6% return
5Y
55%
of 369 industry peers · -78.5% return
No Biotechnology peer with a comparable growth profile has beaten FULC by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is FULC's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology ← 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Fulcrum Therapeutics Earnings Notes12/16/2025
Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

FULCVRTXASPEATYRBBTXCTYMedian
NameFulcrum .Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Mkt Price3.75530.0512.244.8116.2817.6114.26
Mkt Cap0.3134.4----67.3
Rev LTM012,952-0--0
Op Inc LTM-764,288--56---56
FCF LTM-653,202--44---44
FCF 3Y Avg-451,729--58---45
CFO LTM-653,695--44---44
CFO 3Y Avg-452,190--58---45

Growth & Margins

FULCVRTXASPEATYRBBTXCTYMedian
NameFulcrum .Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Rev Chg LTM-10.5%--100.0%---44.8%
Rev Chg 3Y Avg-10.3%--72.3%---31.0%
Rev Chg Q-11.8%--100.0%---44.1%
QoQ Delta Rev Chg LTM-2.9%--100.0%---48.6%
Op Inc Chg LTM6.4%4,760.7%-28.9%--28.9%
Op Inc Chg 3Y Avg-35.4%1,548.2%--10.6%---10.6%
Op Mgn LTM-33.1%----33.1%
Op Mgn 3Y Avg-22.4%----22.4%
QoQ Delta Op Mgn LTM--4.8%-----4.8%
CFO/Rev LTM-28.5%----28.5%
CFO/Rev 3Y Avg-17.4%----17.4%
FCF/Rev LTM-24.7%----24.7%
FCF/Rev 3Y Avg-13.5%----13.5%

Valuation

FULCVRTXASPEATYRBBTXCTYMedian
NameFulcrum .Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
Mkt Cap0.3134.4----67.3
P/S-10.4----10.4
P/Op Inc-3.831.3----13.8
P/EBIT-3.829.5----12.9
P/E-3.733.8----15.0
P/CFO-4.436.4----16.0
Total Yield-26.7%2.9%-----11.9%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-12.5%1.5%-----5.5%
D/E0.00.0----0.0
Net D/E-1.00.0-----0.5

Returns

FULCVRTXASPEATYRBBTXCTYMedian
NameFulcrum .Vertex P.Aspen Ne.aTyr Pha.Bambusa .City The. 
1M Rtn2.7%6.1%-17.8%-30.9%8.6%-21.4%-7.5%
3M Rtn-3.1%0.4%-17.8%-76.1%8.6%-21.4%-10.4%
6M Rtn-36.5%22.0%-17.8%-75.1%8.6%-21.4%-19.6%
12M Rtn-61.1%22.1%-17.8%-82.3%8.6%-21.4%-19.6%
3Y Rtn-9.6%51.2%-17.8%-89.5%8.6%-21.4%-13.7%
1M Excs Rtn4.9%9.1%-14.2%-26.5%12.2%-14.4%-4.6%
3M Excs Rtn-0.3%-0.2%-13.9%-73.8%12.4%-17.6%-7.1%
6M Excs Rtn-37.4%21.2%-18.7%-75.9%7.8%-22.2%-20.5%
12M Excs Rtn-66.8%11.2%-28.1%-93.8%-1.5%-31.6%-29.9%
3Y Excs Rtn-60.8%-25.6%-87.1%-154.8%-59.1%-89.8%-74.0%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Developing small molecules to improve the lives of patients with genetically defined rare diseases0803619
Total0803619


Operating Income by Segment
$ Mil20252024
Developing small molecules to improve the lives of patients with genetically defined rare diseases-85-22
Total-85-22


Net Income by Segment
$ Mil20252024
Developing small molecules to improve the lives of patients with genetically defined rare diseases-75-10
Total-75-10


Assets by Segment
$ Mil20192018
Developing small molecules to improve the lives of patients with genetically defined rare diseases11086
Total11086


Price Behavior

Price Behavior
Market Price$3.75 
Market Cap ($ Bil)0.3 
First Trading Date07/18/2019 
Distance from 52W High-74.3% 
   50 Days200 Days
DMA Price$3.73$5.45
DMA Trenddowndown
Distance from DMA0.5%-31.1%
 3M1YR
Volatility15.9%91.9%
Downside Capture51.2134.35
Upside Capture33.70-67.33
Correlation (S&P 500)43.7%7.9%
FULC Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.460.350.640.030.481.28
Up Beta-0.470.071.023.483.001.67
Down Beta0.420.540.29-1.45-0.011.33
Up Capture59%17%68%-91%-37%51%
Bmk +ve Days12182862130427
Stock +ve Days9142555112361
Down Capture48%54%55%27%31%100%
Bmk -ve Days10253664121325
Stock -ve Days11253263130367

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with FULC
FULC-56.8%91.9%-0.45-
Sector ETF (XLV)24.2%16.9%1.109.9%
Equity (SPY)10.2%13.8%0.457.2%
Gold (GLD)-6.3%28.8%-0.236.0%
Commodities (DBC)31.6%21.3%1.18-15.8%
Real Estate (VNQ)10.0%14.2%0.424.5%
Bitcoin (BTCUSD)-31.4%43.7%-0.7515.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with FULC
FULC-28.3%94.1%0.14-
Sector ETF (XLV)8.6%15.4%0.3620.3%
Equity (SPY)10.9%17.3%0.4623.4%
Gold (GLD)15.5%19.2%0.651.9%
Commodities (DBC)7.1%19.6%0.25-3.4%
Real Estate (VNQ)0.9%19.0%-0.0622.6%
Bitcoin (BTCUSD)-0.6%51.4%0.1716.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with FULC
FULC-12.1%108.7%0.35-
Sector ETF (XLV)12.4%16.8%0.6123.9%
Equity (SPY)14.9%18.0%0.7026.3%
Gold (GLD)11.2%16.6%0.553.4%
Commodities (DBC)7.4%18.2%0.323.2%
Real Estate (VNQ)5.8%20.7%0.2423.8%
Bitcoin (BTCUSD)57.2%66.3%0.9711.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.4 Mil
Short Interest: % Change Since 10152026-4.7%
Average Daily Volume1.3 Mil
Days-to-Cover Short Interest4.8 days
Basic Shares Quantity76.3 Mil
Short % of Basic Shares8.4%

Earnings Returns History

Updated 11/12/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
4/27/2026-1.5%-6.1%-13.8%
2/24/2026-21.2%-28.3%-38.5%
10/29/2025-6.4%-16.3%13.2%
7/29/2025-2.8%-10.9%-16.5%
5/1/202513.8%31.7%78.6%
2/25/20250.0%-12.4%-15.9%
11/13/2024-2.2%-17.3%10.7%
7/31/202410.3%5.5%5.5%
...
SUMMARY STATS   
# Positive141011
# Negative111514
Median Positive5.2%13.9%22.5%
Median Negative-6.4%-8.6%-14.9%
Max Positive125.3%161.0%223.8%
Max Negative-23.0%-39.3%-62.0%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
4/27/2026-1.5%-6.1%-13.8%
2/24/2026-21.2%-28.3%-38.5%
10/29/2025-6.4%-16.3%13.2%
7/29/2025-2.8%-10.9%-16.5%
5/1/202513.8%31.7%78.6%
2/25/20250.0%-12.4%-15.9%
11/13/2024-2.2%-17.3%10.7%
7/31/202410.3%5.5%5.5%
5/13/2024-1.6%1.1%-0.9%
2/27/20244.6%16.4%-6.2%
11/7/202319.5%-3.3%29.0%
8/3/20230.8%3.9%44.8%
5/15/202311.3%-0.6%-3.7%
3/9/2023-23.0%-39.3%-62.0%
1/17/2023-11.2%-8.5%-7.4%
11/8/202215.0%21.4%9.4%
8/11/2022-2.4%-4.5%7.1%
5/9/2022-11.2%-4.1%-6.6%
3/3/20225.4%43.5%113.1%
1/10/20222.8%-8.6%-28.7%
11/4/20213.3%-7.1%-31.5%
8/10/2021125.3%161.0%223.8%
5/6/20215.1%3.3%-13.2%
3/4/2021-14.3%-18.0%-17.8%
11/10/20201.1%11.3%22.5%
SUMMARY STATS   
# Positive141011
# Negative111514
Median Positive5.2%13.9%22.5%
Median Negative-6.4%-8.6%-14.9%
Max Positive125.3%161.0%223.8%
Max Negative-23.0%-39.3%-62.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202607/30/202610-Q
03/31/202604/27/202610-Q
12/31/202502/24/202610-K
09/30/202510/29/202510-Q
06/30/202507/29/202510-Q
03/31/202505/01/202510-Q
12/31/202402/25/202510-K
09/30/202411/13/202410-Q
06/30/202407/31/202410-Q
03/31/202405/13/202410-Q
12/31/202302/27/202410-K
09/30/202311/07/202310-Q
06/30/202308/03/202310-Q
03/31/202305/15/202310-Q
12/31/202203/09/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202607/30/202610-Q
03/31/202604/27/202610-Q
12/31/202502/24/202610-K
09/30/202510/29/202510-Q
06/30/202507/29/202510-Q
03/31/202505/01/202510-Q
12/31/202402/25/202510-K
09/30/202411/13/202410-Q
06/30/202407/31/202410-Q
03/31/202405/13/202410-Q
12/31/202302/27/202410-K
09/30/202311/07/202310-Q
06/30/202308/03/202310-Q
03/31/202305/15/202310-Q
12/31/202203/09/202310-K
09/30/202211/08/202210-Q
06/30/202208/11/202210-Q
03/31/202205/09/202210-Q
12/31/202103/03/202210-K
09/30/202111/04/202110-Q
06/30/202108/10/202110-Q
03/31/202105/06/202110-Q
12/31/202003/04/202110-K
09/30/202011/10/202010-Q
06/30/202008/11/202010-Q
03/31/202005/13/202010-Q
12/31/201903/05/202010-K

Insider Activity

Updated 7/20/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Tang, KevinSee FootnoteBuy72020263.5250,945179,32624,924,926Form
2Tang, KevinSee FootnoteBuy72020263.56116,671415,34925,026,800Form
3Tang, KevinSee FootnoteBuy71520263.56107,377382,26224,611,451Form
4Tang, KevinSee FootnoteBuy71520263.57129,603462,90624,308,960Form
5Tang, KevinSee FootnoteBuy71520263.5412,96645,90023,634,275Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Tang, KevinSee FootnoteBuy72020263.5250,945179,32624,924,926Form
2Tang, KevinSee FootnoteBuy72020263.56116,671415,34925,026,800Form
3Tang, KevinSee FootnoteBuy71520263.56107,377382,26224,611,451Form
4Tang, KevinSee FootnoteBuy71520263.57129,603462,90624,308,960Form
5Tang, KevinSee FootnoteBuy71520263.5412,96645,90023,634,275Form
6Ezekowitz, Alan DirectSell63020263.6518,00065,61439,831Form
7Gould, Robert J DirectSell204202610.7215,000160,8574,877,871Form
8Gould, Robert J DirectSell106202611.8715,000178,0895,578,507Form
9Oltmans, Curtis GaleChief Legal OfficerDirectSell1217202512.923,45244,600132,456Form
10Ra, Capital Management, LPSee footnotesSell1210202513.984,175,13958,377,02184,646,799Form
11Gould, Robert J DirectSell1121202511.0315,000165,4955,349,505Form

Investor Activity (13F)

Updated Nov 18, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Jones Hill Capital LP$13.6 Mil2.9%26New13F
GSK plc$13.7 Mil2.3%13Hold13F
First Turn Management, LLC$17.3 Mil1.9%33ADD +19.2%13F
TCG Crossover Management, LLC$40.3 Mil1.2%49Hold13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Jones Hill Capital LP$13.6 Mil2.9%26New13F
First Turn Management, LLC$17.3 Mil1.9%33ADD +19.2%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Great Point Partners LLC$9.0 Mil2.9%29Exited13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
TCG Crossover Management, LLC$40.3 Mil1.2%49Hold13F
First Turn Management, LLC$17.3 Mil1.9%33ADD +19.2%13F
GSK plc$13.7 Mil2.3%13Hold13F
Jones Hill Capital LP$13.6 Mil2.9%26New13F
Core Cache Last Updated: 11/17/2026